Search

A clinical trial is underway to investigate the relationship between serum elafin levels and disease activity and vascular complications in patients with Behcet Disease (BD). BD is a chronic inflammatory disease characterized by oral and genital ulcers and systemic involvement. Elafin is a protein that inhibits the destructive effects of neutrophil elastase. The trial will use doppler ultrasound to detect intravascular thrombosis and assess vascular wall inflammation. The trial is not yet recruiting and is expected to be completed by April 2025. [Extracted from the article]